300676 华大基因
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.557-6.996-9.5050.9328.278
总资产报酬率 ROA (%)0.413-5.077-6.9030.6645.606
投入资产回报率 ROIC (%)0.485-6.092-8.1810.7766.451

边际利润分析
销售毛利率 (%)41.51537.59141.47249.90352.273
营业利润率 (%)3.449-16.009-22.6223.46315.424
息税前利润/营业总收入 (%)2.103-17.904-24.2171.60114.155
净利润/营业总收入 (%)2.671-17.213-23.5872.15411.474

收益指标分析
经营活动净收益/利润总额(%)213.68421.33644.178206.610115.020
价值变动净收益/利润总额(%)33.347-0.2778.667-28.62638.560
营业外收支净额/利润总额(%)-5.3891.5201.281-30.392-8.057

偿债能力分析
流动比率 (X)2.8132.4232.4192.4062.471
速动比率 (X)2.5662.2342.2082.2232.290
资产负债率 (%)23.10726.75026.07726.51128.945
带息债务/全部投入资本 (%)10.65612.22211.17514.78616.161
股东权益/带息债务 (%)823.544704.770787.159570.761508.284
股东权益/负债合计 (%)328.455270.217279.296273.186242.000
利息保障倍数 (X)-1.79810.86018.603-1.518-118.561

营运能力分析
应收账款周转天数 (天)174.846161.250144.749151.33587.481
存货周转天数 (天)84.17584.22495.741109.04185.318